Navigation Links
AvMed Covers H1N1 Flu Vaccine For Members
Date:10/12/2009

MIAMI, Oct. 12 /PRNewswire/ -- AvMed Health Plans announced that it will cover H1N1 flu administration fees for all of its fully insured members. Co-pays, co-insurance and deductibles will not apply for administration of the H1N1 vaccine even if they have a benefit plan that does not include immunizations.

"AvMed is committed to the health and well-being of our members and we want to ensure that the H1N1 national emergency vaccination effort goes as smoothly as possible," said Kirk Cianciolo, D.O., Senior Vice President and Chief Medical Officer of AvMed Health Plans.

Additionally, AvMed is providing members and employers educational materials related to H1N1 virus, including the following current guidelines and information from the Centers for Disease Control and Prevention (CDC):

The CDC is recommending that programs and providers administer the vaccine to persons in the following five target groups (order of target groups does not indicate priority):

  • Pregnant women,
  • Persons who live with or provide care for infants aged <6 months (e.g., parents, siblings, and daycare providers),
  • Health care and emergency medical services personnel,
  • Persons aged 6 months through 24 years, and
  • Persons aged 25 through 64 years who have medical conditions that put them at higher risk for influenza-related complications.

AvMed is closely monitoring the developments related to the H1N1 flu vaccine. For more information, log on to www.avmed.org or www.cdc.gov/h1n1flu.

About AvMed Health Plans

With more than 35 years in Florida, AvMed is one of the state's oldest and largest not-for-profit health plans, and is solely focused on providing health coverage to Florida citizens and businesses. AvMed is one of only a few health plans in the United States that enjoys dual "Excellent" accreditation status for both its commercial and Medicare health plans from the National Committee for Quality Assurance, the nation's top health care quality evaluator. In addition, AvMed has received an "A," or "Excellent" rating by TheStreet.com Ratings, placing it among the top six percent of all health plans in the United States in terms of financial strength.

SOURCE AvMed Health Plans


'/>"/>
SOURCE AvMed Health Plans
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
2. Video: New Research Discovers Independent Brain Networks Control Human Walking
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
9. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
10. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
11. The Childrens Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohns Disease Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):